Unbiased genetic studies have uncovered surprising molecular mechanisms in human cellular immunity and autoimmunity 1 . We performed whole-exome sequencing and targeted sequencing in five families with an apparent mendelian syndrome of autoimmunity characterized by high-titer autoantibodies, inflammatory arthritis and interstitial lung disease. We identified four unique deleterious variants in the COPA gene (encoding coatomer subunit a) affecting the same functional domain. Hypothesizing that mutant COPA leads to defective intracellular transport via coat protein complex I (COPI) 2-4 , we show that COPA variants impair binding to proteins targeted for retrograde Golgi-to-ER transport. Additionally, expression of mutant COPA results in ER stress and the upregulation of cytokines priming for a T helper type 17 (T H 17) response. Patient-derived CD4 + T cells also demonstrate significant skewing toward a T H 17 phenotype that is implicated in autoimmunity 5, 6 . Our findings uncover an unexpected molecular link between a vesicular transport protein and a syndrome of autoimmunity manifested by lung and joint disease.
Monogenic disorders have proven powerful in elucidating biological mechanisms underlying autoimmunity 7, 8 by showing that autoimmunity can arise from perturbations in several non-classical pathways 7 . Defects in the intracellular trafficking mechanisms of immune cells 9 might also be anticipated to cause autoimmunity, as disruptions in protein trafficking lead to endoplasmic reticulum (ER) stress and activation of the unfolded protein response (UPR), both of which have been implicated in autoimmune disease 10 .
We identified five families with a previously undescribed mendelian syndrome of autoimmunity manifested by high-titer autoantibodies, interstitial lung disease and inflammatory arthritis ( Fig. 1a-d , Table 1 and Supplementary Table 1 ). The average age of presentation was 3.5 years, with a range of 6 months to 22 years. Several patients presented with pulmonary hemorrhage requiring immunosuppression, and all patients have lung disease ( Table 1 and Supplementary Table 1) . A comparison of lung biopsies from unrelated patients identified lymphocytic interstitial infiltration with germinal center formation (Fig. 1b,c) , findings consistent with the interstitial lung disease occurring in systemic autoimmune syndromes 11 . Immunohistochemical staining of lungs identified CD20 + B cells within the germinal centers and substantial numbers of lung-infiltrating CD4 + T cells (Fig. 1b,c) . Autoantibodies were detected in 86% of the affected patients, including anti-nuclear antibodies (ANAs), anti-neutrophil cytoplasmic antibodies (ANCAs) and rheumatoid factor (RF) ( Table 1  and Supplementary Table 2 ). Immunoglobulin levels, absolute lymphocyte counts and CD4/CD8 cell ratios were largely normal (Supplementary Table 3 ). Ninety-five percent of the patients have arthritis, and some initially presented with joint pain. Four unrelated patients underwent renal biopsies that demonstrated immune-mediated COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis renal disease ( Supplementary Fig. 1 and Supplementary Table 1) , providing further evidence of autoimmunity. All patients have required long-term immunosuppression.
We enrolled patients for whole-exome sequencing to identify genetic variants potentially associated with disease. Family pedigrees suggested autosomal dominant inheritance with incomplete penetrance (Fig. 1d) . We obtained whole-exome sequencing data for patients A.III.6, A.IV.1 and B.III.1 and carried out analysis to identify shared variants. There was only one gene, COPA, observed to have variants in both families, with the two individuals in family A having a c.698G>A (p.Arg233His) variant and individual B.III.1 from family B having a c.728A>G (p.Asp243Gly) variant (NM_004371.3). These variants had not been identified in several large databases 12 . The variants cosegregated with the disease phenotype, and we identified them in all other affected family members ( Supplementary  Fig. 2) . For family C, we performed whole-exome sequencing analysis and direct sequencing for five affected individuals (C.IV.1, C.IV.2, C.IV.15, C.V.1 and C.V.9) and four unaffected pedigree members (C.III.2, C.III.10, C.IV.16 and C.V.8) and identified a c.721G>A (p.Glu241Lys) COPA variant on chromosome 1 to be the only rare, shows incomplete penetrance, with one unaffected carrier over four generations. Family B (c.728A>G) shows incomplete penetrance of severe disease in females affected over three generations. Family C (c.721G>A) shows incomplete penetrance of severe disease and segregation of the mutation within affected patients over six generations. In family D (c.690G>T), there is an unaffected mutation carrier who is 1 year old, below the age of onset. Family E (c. 698G>A) shows complete penetrance over two generations. Square, male; circle, female; black filled, affected with severe disease; unfilled, unaffected; slash, deceased; asterisk, submitted for whole-exome sequencing; vertical line, unaffected carrier. Roman numerals represent the generation within the family, and Arabic numerals designate individuals within the generation.
l e t t e r s npg l e t t e r s nonsynonymous variant that segregated with the disease phenotype ( Table 2 and Supplementary Fig. 2 ). Table 4 ). Overall, we employed whole-exome sequencing and targeted sequencing at two institutions and independently identified four unique variants in five affected families. Within these 5 families, 21 of 30 COPA mutation carriers were affected by disease whereas 9 were unaffected clinically, consistent with incomplete penetrance. Notably, all variants identified were predicted to be deleterious and mapped to a 14-residue region in the highly conserved, functionally important WD40 domain of the COPA protein 3 ( Fig. 2a and Table 2 ).
To provide statistical evidence that variants in COPA are involved in disease etiology, we performed an affected-only parametric linkage analysis on the four families that were informative, analyzing the COPA missense variants in these families 13 . No accurate estimate of the penetrance for this rare phenotype exists. We assumed that the disease allele frequency and variant allele frequency were both 0.001. The four informative pedigrees provided the following logarithm of odds (LOD) scores at θ (recombination fraction) = 0 for the identified COPA variants: family A, 1.5; family B, 0.90; family C, 2.7; family D, 0.60. The combined statistically significant LOD score of 5.7 for these families provides statistical evidence that COPA is involved in disease etiology. Given that we observed four variants of the COPA gene in five affected families, that the rare variants cosegregated with the disease and that the variation at this locus is linked to the autoimmunity phenotype, we conclude that it is highly likely that pathological variants in COPA are the underlying cause of this syndrome.
COPA encodes the COPA subunit of COPI. COPI and COPII are carrier complexes required for membrane trafficking between the ER and the Golgi. COPII facilitates the anterograde movement of newly created proteins or lipids from the ER toward the cell surface, whereas COPI is engaged in the retrograde movement of proteins from the Golgi to the ER 14 . To investigate potential mechanisms by which the COPA variants might lead to disease, we measured the levels of COPA transcript and COPA protein and found no difference in expression levels between patient and control B-lymphoblastoid cell lines (BLCLs) (Supplementary Fig. 3a-c) . Imaging analysis demonstrated that the COPA variants did not cause aggregation or mislocalization of COPA protein thereby impairing its function 4 (Supplementary Fig. 3d ).
Given that COPA was expressed at normal levels in patients, we sought to determine a functional consequence of the COPA variants. Notably, point mutations mapping to the COPA WD40 domain in yeast, analogous to the disease-associated damaging alleles identified in the patients, impair binding of dilysine-tagged proteins and cause a defect in retrograde transport 2, 3, 15 . To test whether binding of dilysine proteins to the COPA mutants identified was similarly impaired, we generated a synthetic peptide corresponding to the cytoplasmic tail of yeast Wbp1 (Wbp1p peptide), which bears a dilysine retrieval signal that binds to mammalian COPA 2, 16 . We incubated recombinant COPA protein with Wbp1p peptide and found that Glu241Lys mutant COPA had impaired binding to Wbp1p peptide in comparison to wild-type COPA (Fig. 2b) . We next transfected cell lines stably expressing Glu241Lys mutant COPA with a construct for a reporter protein bearing a dilysine retrieval signal. In the subsequent immunoprecipitation assays, we also found impaired binding of the dilysine reporter to Glu241Lys mutant COPA (Fig. 2c) . We obtained comparable results in experiments using Lys230Asn mutant COPA (Supplementary Fig. 4 ). Taken together, these results demonstrate that mutant COPA bearing a WD40 variant identified in patients behaves in an anomalous way, analogous to the altered activity observed for the point mutations in yeast shown to cause a defect both in the binding of dilysine-tagged proteins and retrograde transport 2, 3, 15 .
We next sought to identify physiological effects of mutant COPA that might be linked mechanistically to autoimmune disease. Defects phyloP, phastCons and GERP scores for nucleotide conservation were derived from the UCSC Genome Browser. PolyPhen-2, SIFT, LRT, MutationAssessor and MutationTaster provided a functional prediction for each missense variant. For Combined Annotation-Dependent Depletion (CADD), a scaled C score ≥10 places a variant within the top 10% of likely deleterious variants, whereas a C score ≥20 indicates that the variant is within the top 1% of likely deleterious variants across the genome.
npg l e t t e r s in the COPI pathway, including ones caused by WD40 variants in COPA 2, 3, 15 , have been shown to affect retrograde trafficking and to also indirectly affect COPII-mediated anterograde trafficking from the ER to the Golgi 4 . Thus, we hypothesized that the COPA variants in patients likewise impair intracellular protein trafficking and, as a result, lead to ER stress and activation of the UPR 4, 17 . Notably, ER stress and activation of the UPR have been linked to autoimmunity and lung disease 10, 18, 19 . To determine whether patients exhibited increased ER stress, we examined lung biopsies for expression of the molecular chaperone binding immunoglobulin protein (BiP) 20 . We found that BiP levels were markedly increased in the lung epithelium and alveolar macrophages of patients in comparison to controls ( Fig. 3a and Supplementary Fig. 5a ,b), consistent with our hypothesis. We next performed dynamic functional assessments of patientderived cells for evidence of enhanced ER stress caused by mutant COPA. We treated BLCLs from patients with low levels of thapsigargin, an inhibitor of the ER Ca 2+ ATPase used experimentally to induce ER stress. Cells from patients with COPA variants had significantly elevated levels of transcript for HSPA5 (which encodes BiP) ( Fig. 3b and Supplementary Fig. 5c ) in comparison to control cells from related and unrelated individuals (P < 0.05). Interestingly, the clinically asymptomatic COPA mutation carriers (with apparent non-penetrance) demonstrated a weaker increase in ER stress in comparison to those severely affected (Fig. 3b) , suggesting that the mutation's effect on healthy carriers is below a threshold required for clinical disease.
To establish the specific role of mutant COPA in the induction of ER stress, we performed small interfering RNA (siRNA)-mediated knockdown experiments in HEK (human embryonic kidney) cells. Indeed, we found that reducing COPA expression resulted in higher levels of ER stress, as indicated by a marked increase in HSPA5 (BiP) expression (Fig. 3c) . To demonstrate that the increased ER stress in patient-derived cells was specifically due to mutant COPA, we overexpressed wild-type or mutant COPA in HEK cells ( Supplementary  Fig. 5e ,f). Consistent with a dominant-negative effect of the mutations, presence of any of the four COPA mutations identified in patients resulted in elevated HSPA5 (BiP) levels in comparison to cells transfected with wild-type COPA (Fig. 3d and Supplementary  Fig. 5d ). The levels of additional ER stress markers such as ATF4 and DDIT3 (CHOP) were also significantly increased when COPA expression was reduced or mutant COPA was present ( Supplementary  Fig. 5g,h) . Given the role of autophagy in alleviating ER stress 21 Fig. 8a,b) . This constellation of findings suggests a baseline defect in autophagic function that might be due to impaired early endosomal function in patients 24 . Thus, it is possible that impaired autophagy exacerbates the increase in ER stress caused by mutant COPA 25 . In aggregate, our findings demonstrate that the expression of mutant forms of COPA in patients is sufficient for the induction of ER stress.
Finally, to investigate potential immunological links between mutant COPA and the clinical phenotype, we examined CD4 + T cells, given their high numbers in diseased lungs (Fig. 1b,c) and their critical function in autoimmune disease 26 . Interestingly, recent studies have shown that ER stress has a role in the generation of T H 17 cells [27] [28] [29] [30] , a CD4 + effector T cell population implicated in autoimmunity 5, 6 , by causing antigen-presenting cells (APCs) to secrete cytokines necessary for the induction and expansion of T H 17 populations. Thus, we hypothesized that mutant COPA might lead to the production of T H 17 cells through a similar mechanism.
Given that B cells are professional APCs, we tested our BLCLs for the expression of cytokines involved in the generation of the CD4 + T H 1, T H 2 and T H 17 helper T cell subsets. Patient-derived BLCLs with mutant COPA showed a significant elevation in the levels of transcripts encoding interleukin (IL)-1β, IL-6 and IL-23 (p19 and p40 subunits) (Fig. 4a) , cytokines that are critical for the priming and expansion of T H 17 populations 31 , and this effect was enhanced by ER stress. In contrast, transcript levels for the T H 2-priming cytokine IL-4 in patients were similar to those in controls, whereas transcript levels for the T H 1-priming cytokine IL-12 (p35 subunit) were very low in both groups (Fig. 4a) . Transcript levels for IL-10 and transforming growth factor (TGF)-β were not different between patients and controls, and interferon (IFN)-α (IFNA2) levels in patients were Fig. 9 ). To determine whether CD4 + T cells in patients demonstrated an immunological phenotype consistent with this pattern of cytokine expression, we profiled peripheral blood mononuclear cells (PBMCs). Intracellular cytokine staining demonstrated equal frequencies of IL-13-secreting T H 2 cells among patient and control cells (Fig. 4b,c) . By contrast, patient CD4 + T cells demonstrated a marked skewing away from IFN-γ-secreting T H 1 cells and a significant increase in the frequency of IL-17A-secreting T H 17 cells (Fig. 4b,c and Supplementary Fig. 10 ). Thus, mutant COPA leads both to higher levels of ER stress in patient-derived BLCLs and the production of cytokines that promote the expansion of T H 17 populations. Through genetic studies in five unrelated families, we provide evidence that point mutations affecting a 14-residue region of the WD40 domain of COPA cause a systemic autoimmune syndrome of lung and joint disease. Functional analyses demonstrate that mutant COPA is unable to bind proteins with dilysine-based motifs and provide evidence of defective intracellular trafficking. Specifically, we show that expression of mutant COPA in cells induces higher levels of ER stress, which may be further exacerbated in patients by impaired autophagy 25 . Finally, we establish a putative immunological mechanism for COPA mutations in disease by showing that mutant COPA via ER stress leads to a cytokine milieu that promotes the generation of T H 17 cells, a cell population shown to mediate autoimmunity 5, 6 .
It may seem unusual that mutation of a ubiquitously expressed protein in an essential trafficking pathway leads to an autoimmune syndrome restricted to the lung and joints. However, there are several disorders in which alterations to widely expressed proteins lead to distinct clinical phenotypes 32, 33 . For instance, four mendelian syndromes with disparate clinical manifestations result from mutations affecting the COPII trafficking machinery 34 . We can only speculate that, in patients with COPA mutations, there are tissuespecific cells central to the disease that are sensitive to alterations in COPA function. In addition, given the reduced penetrance of disease, there may be differences attributable to sex or other genetic and environmental factors that dictate whether a carrier of a mutant COPA allele develops clinical disease.
Future studies may elucidate how defects in COPA lead to ER stress and autoimmunity. ER stress and the UPR have been strongly associated with the pathogenesis of inflammatory and autoimmune disorders, in part through the intersection of key pathways that lead to activation of nuclear factor (NF)-κB or alterations in antigen presentation 10, 18 . Furthermore, because the COPA mutations identified are predicted to impair retrograde transport, proteins destined for return to the ER may instead escape the cell or be presented in tissue sites to prime autoreactive immune responses 35 . Interestingly, both ER stress and T H 17 cells have previously been implicated in patients with interstitial lung disease 19, 36, 37 and inflammatory arthritis 10, 38, 39 , including rheumatoid arthritis 5 . It remains unknown whether T H 17 cells in COPA-mutant patients are pathogenic or arise as a result of inflammation. The role of regulatory T cells also needs to be determined. In conclusion, the discovery of a molecular link between a defect in the COPI vesicular trafficking machinery and a new syndrome of autoimmunity defines a starting point for understanding Results are shown for data pooled from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001. l e t t e r s the role of intracellular transport in the induction of human autoimmunity and as a potential therapeutic target in disease. Genomic DNA preparation. DNA was isolated from clotted whole blood by using the Clotspin Baskets and the Gentra PureGene Blood kit (Qiagen) according to the manufacturer's instructions.
URLs. BCM-HGSC protocol
Exome sequencing. Library preparation. DNA samples were constructed into Illumina paired-end pre-capture libraries according to the manufacturer's protocol (Illumina Multiplexing_SamplePrep_Guide_1005361_D) with modifications as described in the BCM-HGSC protocol (see URLs). Libraries were prepared using Beckman robotic workstations (Biomek NXp and FXp models). Briefly, 1 µg of DNA was sheared into fragments of approximately 300-400 bp with the Covaris E210 system and was end repaired, A tailed and ligated into Illumina multiplexing paired-end adaptors. Pre-capture ligation-mediated PCR (LM-PCR) was performed for 6-8 cycles of amplification using 2× SOLiD Library High-Fidelity Amplification Mix (a custom product manufactured by Invitrogen). Purification was performed with Agencourt AMPure XP beads after enzymatic reactions, and, after the final purification, the amount and size distribution of the pre-capture LM-PCR product was determined using the LabChip GX electrophoresis system (PerkinElmer).
Capture enrichment. The pre-capture libraries were pooled as a 4-plex (approximately 500 ng/sample, 1 µg per pool) and hybridized in solution to the HGSC CORE design 40 (52 Mb; NimbleGen) according to the manufacturer's protocol (NimbleGen SeqCap EZ Exome Library SR User's Guide) with minor revisions. Human Cot-1 DNA and full-length Illumina adaptorspecific blocking oligonucleotides were added into the hybridization to block repetitive genomic sequences and the adaptor sequences, and post-capture LM-PCR amplification was performed using 2× SOLiD Library High-Fidelity Amplification Mix with 14 cycles of amplification. After the final SPRI bead purification step, the quantity and size of the capture library was analyzed using an Agilent BioAnalyzer 2100 DNA Chip 7500. The efficiency of the capture was evaluated by performing a qPCR-based quality assay on the four standard NimbleGen internal controls. Successful enrichment of the capture libraries was estimated to range from a ∆C t value of 6 to 9 over the nonenriched samples.
Sequencing. Library templates were prepared for sequencing using Illumina's cBot cluster-generation system with TruSeq PE Cluster Generation kits. Briefly, these libraries were denatured and diluted in hybridization buffer to achieve a load density of ~800,000 clusters/mm 40 . The library pool was loaded on a single lane of a HiSeq flow cell, with 2% phiX control library spiked into the lane for run quality control. The sample libraries then underwent bridge amplification to form clonal clusters, followed by hybridization with the sequencing primer. The sequencing run was performed in paired-end mode using the Illumina HiSeq 2000 platform. Using TruSeq SBS kits, sequencing-by-synthesis reactions were extended for 101 cycles from each end, with an additional 7 cycles for the index read. With the sequencing run yielding an average of ~8.4 Gb per sample, samples achieved an average of 89% of the targeted exome bases covered to a depth of 20× or greater.
Primary data analysis for families A and B. Initial sequence analysis was performed using the HGSC Mercury analysis pipeline 41 (see URLs). In summary, the primary analysis software on the instrument produces .bcl files that are transferred off the instrument into the HGSC analysis infrastructure by the HiSeq Real-Time Analysis module. Once the run is complete and all .bcl files are transferred, Mercury runs the vendor's primary analysis software (CASAVA), which demultiplexes pooled samples and generates sequence reads and base call confidence values (qualities). The next step is the mapping of reads to the GRCh37 human reference genome (see URLs) using the Burrows-Wheeler aligner (BWA 41 ; see URLs) and producing a BAM 42 (binary alignment/map) file. The third step involves quality recalibration using the Genome Analysis Toolkit (GATK; see URLs) and, where necessary, the merging of separate sequence-event BAMs into a single sample-level BAM. BAM sorting, duplicate read marking and realignment to improve indel discovery all occur at this step.
Confirmation of sequencing results. The candidate disease-associated mutations identified by whole-exome sequencing were independently confirmed by Sanger sequencing and analyzed for familial segregation.
Primary data analysis of families C and D. Nine samples in family C (C.III.2, C.III.10, C.IV.1, C.IV.2, C.IV.15, C.IV.16, C.V.1, C.V.8 and C.V.9) and 11 samples in family D (D.I.2, D.II.1, D.II.3-D.II.5 and D.III.1-D .III.6) were sent to the University of California San Francisco Genomics Core for whole-exome sequencing. Library preparation, capture enrichment and sequencing were performed similar to the methods used for families A and B. Sequencing reads were aligned to the hg19 reference genome using BWA (v0.5.9) with the default parameter that allows for two mismatches. Indexing, realignment and duplicate removal were then performed using Picard (v1.56) and SAMtools (0.1.18). Variants were called and recalibrated using GATK 42, 43 , version 1.4-25-g23e7f1b, and hard filtered with the recommendations listed in Best-Practice Variant Detection in GATK v3 with 'QD < 2.0' , 'MQ < 40.0' , 'FS > 60.0' , 'HaplotypeScore 13.0' , 'MQRankSum < 12.5' , 1 'ReadPosRankSum < -8.0' for SNPs. The filtered list was then annotated with snpEff v2.0.5 in GRCh37.64 with information from public databases to determine the significance of new sequence alterations, including the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project, 1000 Genomes Project database and dbSNP132. A filtering analysis of the exome variants in the nine subjects in family C was performed in VarSifter 44 . The filtering strategy was designed to find variants shared among 6 carriers that were not seen in 3 related controls or in 20 other whole-exome sequences generated for unrelated control subjects. We also excluded variants with a minor allele frequency (MAF) >0.001. This filtering analysis yielded a single rare variant in COPA (c.721G>A) that was shared by affected subjects and not present in any control. The filtering strategy in family D was performed similarly to that employed for family C to identify a variant in COPA (c.690G>T) that cosegregated with the disease phenotype.
Plasmids and stably transfected cell lines. pCMV6-Entry vectors encoding Myc-DDK-tagged or untagged human COPA (Origene) were used as the parental vectors for mutant plasmid generation. Mutant plasmids were created via site-directed mutagenesis using the QuikChange Lightning kit (Agilent Technologies) according to the manufacturer's instructions or a third-party service (Epoch Life Sciences). CD8A sequence spanning residues 1 through 207 was subcloned from human cDNA into the pCMV6-Entry vector. A sequence encoding mTagGFP at the N terminus was added to the CD8α sequence, and a sequence encoding residues KYKSRRSFIDEKKTN including the dilysine motif KKTN at the C terminus was added. Cell lines stably expressing wild-type or Glu241Lys mutant COPA-Flag fusion protein in the presence of doxycycline were generated with the Flp-In T-REx system (Invitrogen). For microscopic analysis, HEK293T cells stably expressing GFP-LC3 were electroporated using the Amaxa 4D nucleofector system according to the manufacturer's protocol. Briefly, HEK293T cells were grown to 80% confluence. Then, 1 × 10 6 cells were nucleofected with 2 µg of plasmid DNA encoding the COPA mutants. After 24 h, cells were collected and imaged.
Generation and stimulation of B-lymphoblastoid cell lines. Exponentially growing B95-8 cells were seeded at 1 × 10 6 cells/ml and incubated for 3 d at 37 °C in 5% CO 2 . B95-8 supernatant was collected by centrifugation at 300g at 4 °C and passed through a 0.45-µm filter. PBMCs were resuspended at 1-5 × 10 6 cells/ml in RPMI-1640 medium supplemented with 20% FBS followed by the addition of 0.5-1 volumes of B95-8 supernatant with or without 10 µg of a human TLR9 ligand (ODN 2006, Class B CpG oligonucleotide, Invivogen). Cells were incubated overnight at 37 °C in the presence of 5% CO 2 and 0.5 µg/ml cyclosporine A, and an equal volume of medium was added the next day. Cells were cultured until they formed macroscopically visible clusters and then maintained at concentrations of 0.5-1 × 10 6 cells/ml. For ER stress induction, Epstein-Barr virus (EBV)-transformed cells were seeded at 1 × 10 6 cells/ml and incubated with 100 nM thapsigargin (Sigma) for 6 h. Cells were collected, washed in PBS and processed for RNA isolation.
RNA isolation and quantitative PCR analysis. RNA was isolated with the RNeasy Mini kit (Qiagen). SuperScript III Reverse Transcriptase (Invitrogen) was used to synthesize cDNA. qPCR was performed with TaqMan Gene Expression assays from Life Technologies (COPA, Hs00189232_m1; HSPA5 (BiP), Hs00607129_gH; GAPDH, Hs02758991_g1; IL23p19, Hs00900828_g1; IL12p35, Hs01073447_m1; IL12p40, Hs01011519_m1; IL6, Hs00985639_m1; IL1B, Hs01555410_m1; IL4, Hs00174122_m1) or by using Qiagen SYBR green for ACTB, DDIT3 or ATF4 (sequences in Supplementary Table 5 ).
Routine and immunohistochemical staining of lung biopsy tissues. Lung biopsies from the patients were fixed in 10% buffered formalin and routinely processed for paraffin embedding. The resulting formalin-fixed, paraffinembedded lung biopsy tissues were sectioned, resulting in glass slides with 5-µm tissue sections that underwent routine hematoxylin and eosin staining and immunohistochemical staining. Tissue section staining was performed by the University of California San Francisco and/or Texas Children's Hospital Pathology Laboratories certified by the College of American Pathologists, employing procedures certified by the College of American Pathologists, with appropriate positive and negative controls and using automated hematoxylin and eosin (Leica Microsystems) and immunohistochemical (Leica Bond III Automated Immunohistochemical and In Situ Hybridization Biosystem, Leica Microsystems) staining systems. Epitope antigen retrieval was performed using a proprietary automated system employing citrate-based buffer and surfactant proprietary kits (Novocastra Bond Epitope Retrieval Solutions 1, Leica Microsystems). Proprietary antibody kits (Leica Microsystems) for CD20, CD4 and CD8 were used with appropriate positive and negative control tissues. Immune infiltrates of organs were confirmed by an independent reading of the slides by a blinded observer.
For BiP staining, microwave antigen retrieval was performed on deparaffinized and rehydrated lung sections with sodium citrate (pH 5.5). After peroxidase blocking (3% H 2 O 2 ) and blocking with 1% BSA and 3% goat serum, sections were stained with antibody to BiP (Abcam, ab21685) overnight. BiP staining was visualized with biotinylated goat anti-rabbit antibody (Jackson ImmunoResearch Laboratories) and Elite ABC reagent followed by DAB staining (Vector Laboratories). Slides were counterstained with Mayer's hematoxylin. Images were obtained using a standard histology microscope and captured with an AxioCam using AxioVision software (Carl Zeiss MicroImaging).
Binding assay and immunoblot. The Flp-In T-REx 293 cells described above were cultured for 2 d in the presence of doxycycline to induce wild-type or mutant COPA-Flag overexpression. Cells were then lysed in 500 µl of lysis buffer (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40 and 5% glycerol). A synthetic peptide (Genscript) representing the cytoplasmic tail of yeast Wbp1 (Wbp1p peptide; CKKLETFKKTN) was covalently linked to SulfoLink resin (Pierce) according to the manufacturer's protocol. Cell lysate containing 80 µg of protein was added to 20 µl of resin in 0.5 ml of binding buffer (200 mM NaCl, 20 mM Tris-HCl, pH 7.4, 7.5 mM MgCl 2 , 5% glycerol and 0.2% Triton X-100) and gently rotated at room temperature for 5 min. Resin was subsequently washed by inverting eight times in 1 ml of binding buffer and lastly boiled in SDS-PAGE sample buffer to release bound COPA. For immunoprecipitation, Flp-In T-REx 293 cells cultured in the presence of doxycycline were transfected with the GFP-CD8-KKTN construct for 36 h. Cells lysates were precleared with Sepharose beads and then incubated with antibody to CD8 (Abcam, ab85792) covalently linked to Sepharose beads. Protein-bead complexes were washed and boiled in SDS-PAGE sample buffer. Proteins were subjected to SDS-PAGE and transferred to PVDF, and membranes were blocked and probed with one of the following antibodies: a horseradish peroxidase (HRP)-conjugated monoclonal antibody against Flag (Sigma, A8592), a mouse monoclonal antibody to mGFP (Origene, TA180076), a rabbit antibody to COPA (Sigma, HPA028024) or a mouse antibody to GAPDH (Santa Cruz Biotechnology, sc-32233). Bands were detected by incubation with secondary HRP-coupled antibodies and SuperSignal West Femto (Pierce) chemiluminescence.
Flow cytometry. PBMCs were suspended in FACS buffer (PBS with 2% FCS and 1% sodium azide) at 1 × 10 6 cells per well of 96-well culture plates and incubated for 4 h in the presence of brefeldin A (Sigma) with or without PMA (70 ng/ml) and ionomycin (700 ng/ml). For evaluation of surface receptors, cells were stained with the viability Ghost Dye violet 510 (Tonbo) and monoclonal antibodies, including anti-CD3 clone SKY7 (BioLegend) and anti-CD4 clone OKT4 (BioLegend). Cells were incubated with antibodies at room temperature for 20 min and then washed with FACS buffer. For intracellular staining, cells were permeabilized with Cytofix/Cytoperm reagent (BD) and incubated for 30 min at room temperature after incubation with anti-IFN-γ clone 4S.B3 (eBioscience), anti-IL-17A clone eBio64CAP17 (eBioscience) or anti-IL-13 clone PVM13-1 (eBioscience). Samples were acquired using a Fortessa flow cytometer (BD Bioscience) and analyzed using FlowJo software.
Statistical analysis. Statistical analyses were performed using Prism 6.0 (GraphPad Software). Statistical comparison was made using either Mann-Whitney U tests or the Student's t tests as indicated in the figure legends. Welch's t test was applied when variances were unequal. Comparison between more than two experimental groups was made using one-way ANOVA, followed by Dunnett's post-hoc test. P < 0.05 was considered statistically significant.
Genotype analysis.
We performed OMNI Express high-resolution cSNP arrays (~720,000) for families A (IV.1, III.1 and III.2) and E (II.1, I.1 and I.2). We used the data to obtain the length of the haplotype block around the causative COPA mutations shared by affected individuals in two families. For each family, we phased and compared the genotype calls for each trio to identify the haplotypes inherited by affected family members. The haplotype analysis of cSNP data was performed using custom scripts implemented in the R statistical programming language.
Autophagy stimulation and detection. Functional and biochemical analyses were performed using the following reagents: Torin1 (EMD Millipore Chemicals); baflomycin A1 (Sigma-Aldrich); guinea pig antibody to the C terminus of p62 (American Research Product, 03-GP62-C); rabbit antibody to LC3B (Novus Biologicals, NB100-2220); rabbit antibody to S6 ribosomal protein phosphorylated at Ser235/Ser236 (Cell Signaling Technology, 4858); mouse monoclonal antibody (54D2) to S6 ribosomal protein (Cell Signaling Technology, 2317); mouse monoclonal antibody to GAPDH (Sigma-Aldrich, G8797); and infrared fluorescent dye-conjugated secondary antibodies (Li-Cor). To perform the experiments, an mTOR-specific inhibitor Torin1 was used to induce autophagy, and a lysosome inhibitor bafilomycin A were used to block the degradation of autophagy content by lysosome. Briefly, cells (2 × 10 6 ) were treated with vehicle only, 250 nM Torin1 or 250 nM Torin1 together with 200 nM bafilomycin A for 4 h. Cells were washed twice with PBS and lysed on ice for 30 min in GFB buffer (40 mM Bis-Tris propane, 150 mM NaCl, 1% Triton X-100, 10% glycerol) supplemented with 1× PIC (protease inhibitor cocktail, BD Biosciences) and 1× Phosphatase Inhibitor Cocktail (Thermo Scientific). After centrifugation at 5,000g for 1 min, protein concentrations in cell lysate supernatants were measured using BCA protein assay reagents (Thermo Scientific). Cell lysates (25 µg of protein) were then heated at 95 °C for 5 min in 1× LDS sample buffer (Invitrogen) and resolved by SDS-PAGE (Invitrogen). Proteins were transferred to nitrocellulose membranes using a wet transfer cell system (Invitrogen). Membranes were blocked with blocking buffer (Li-Cor) for 1 h, followed by a 2-h incubation with primary
